Evidence map›Paper›PMID 36929133›Full record

ArticleHLA2023

HLA-B leader genotypes in a clinical population.

Gansuvd Balgansuren, Maggie Sprague, Paula Peterson, Yasaman Shenavar, Ada Ng, Lois Regen, Nakita Shelton, Effie Petersdorf

Abstract read
In one paragraph

Article in HLA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gansuvd BalgansurenClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-5446-9176
Maggie SpragueClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Paula PetersonClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Yasaman ShenavarClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Ada NgClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Lois RegenClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Nakita SheltonClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Effie PetersdorfClinical Immunogenetics Laboratory, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Fred Hutch Cancer Center · USUniversity of Washington · US

Funding

Hematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9M
Clinical Significance of MHC Haplotypes in Hematopoietic Cell TransplantationR01CA100019 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERSDORF, EFFIE W · 2003 to 2025
$9.1M
Immuno and Epigenetics of Hematopoietic Cell TransplantationR01CA218285 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2017 to 2026
$5.6M
Immunogenetics of Outcomes Disparities After Allogeneic HCTR01CA231838 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2018 to 2026
$3.7M
NCI NIH HHS R01 CA100019NCI NIH HHS R01 CA218285NCI NIH HHS R01 CA231838NIAID NIH HHS U01 AI069197
6 · The paper itself

Abstract

The -21 dimorphism in the leader sequences of HLA-B exon 1 is associated with risk of graft-versus-host disease (GVHD), relapse and overall survival after unrelated donor hematopoietic cell transplantation (HCT), haploidentical HCT and cord blood transplantation. Consideration of the leader dimorphism in the prospective selection of allogeneic donors for HCT may help to lower risks for patients, but requires understanding of the frequencies of the leader in patients and candidate transplant donors. We defined the frequencies of the HLA-B leader, and its association to HLA-B Bw4/Bw6 and C1/C2 KIR epitopes. Sequence variants of rs1050458 of exon 1 position -21 for 11,126 haplotypes were analyzed from high resolution HLA typing of over 5500 study subjects. HLA typing was performed by TruSight/AlloSeq NGS and analyzed using TruSight/AlloSeq Assign software. HLA-B Bw4/Bw6 and C1/C2 KIR epitopes were defined based on established sequence alignments and nomenclature. Alleles at rs1050458 of HLA-B exon 1 were validated as dimorphic: rs1050458-C or -T variants encoding threonine (T) or methionine (M) at anchor position 2 (P2) of nonameric HLA-B leader peptides, respectfully. No additional variants were observed. Among study subjects, 70% of HLA-B haplotypes encoded T-leader and 30% encoded M-leader sequences. The genotype frequencies of TT, MT, and MM were consistent among patient, related, and unrelated donor groups. The associations of M/T leader, Bw4/Bw6, and C1/C2 enhanced understanding of the Class I features involved in the innate immune response. A population of patients and transplant donors confirms the rs1050458 leader dimorphism and its association with HLA-B Bw4/Bw6 and C1/C2 KIR features.

Indexed as

Hematopoietic Stem Cell TransplantationReceptors, KIRAllelesEpitopesGenotypeHLA-B AntigensHumansProspective StudiesEpitopesHLA-B AntigensReceptors, KIRgenotypeHLA-B leader sequenceM-leader peptideNGSrs1050458-C/TT-leader peptide

Identifiers

PMID36929133
PMCPMC13387073
OpenAlexW4327566603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.